Modality platforms
- Proteins and peptides: Discovery and development of therapeutic proteins, peptides and antibodies, including alternative delivery of biologics e.g., oral or extended release
- RNA-based therapies: Biological processes to silence and alter genes that cause or contribute to diseases. Tissue targeting technologies and innovation to improve manufacturability/scalability
- Small molecules: Pre-clinical and clinical assets in core TAs, as well as development and production capabilities
- Gene and cell therapies: Targeting DNA to deliver a true cure for genetic diseases. Specialised cells and technology/devices for regenerative or curative cell therapies
- Emerging, novel and next-generation technologies with disruptive potential
Integrated care
- Digital: Solutions to improve outcomes and adherence through digital therapeutics, diagnostics, monitoring, prediction of disease progression and risk management
- Data: To improve patient outcomes and drug discovery through access and products in patient, clinical, non-clinical data, discovery, research, analytics and scientific data sources
- Diagnostics: To identify the right patient, predict and diagnose the disease and comorbidities, monitor outcomes and treatment response through in vitro, behavioural and digital tests
- Devices: Connected solutions to enable patient insight and simple to use delivery systems
Diabetes
- Next generation innovation in GLP-1/incretin-based therapies and insulin
- Novel mechanisms and disease modifying therapies in type 1 and type 2 diabetes
Obesity
- Novel and/or complementary approaches to energy intake and energy expenditure regulation
- Quality of weight loss and co-morbidity improvements, as well as transformational prevention approaches
Rare disease
- Novel bypassing agents, cell and gene-therapies within rare blood and haemato-renal disorders
- Rare adrenal, pituitary and growth diseases within rare endocrine disorders
Cardiovascular diseases
- Novel modalities for atherosclerosis and chronic heart failure
- Novel MoAs in anti-inflammatory or other pathways across multiple indications
Please note: Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.